Elan shareholders approve buyback in blow to Royalty bid
DUBLIN, June 17
DUBLIN, June 17 (Reuters) - Elan shareholders approved a share buyback on Monday, meaning U.S.-based Royalty Pharma's hostile bid for the Irish drug firm will lapse unless a legal challenge it has mounted succeeds.
Royalty last month made its takeover offer conditional on shareholders rejecting four resolutions at a meeting on Monday. It won an Irish court injunction against a regulator last week, allowing it to appeal against a ruling that it cannot change the conditions attached to its offer.
Shareholders rejected Elan's proposed $1 billion royalties deal with U.S company Theravance Inc, the purchase of a private drug firm and a drug spin-off in a major blow to the company's plans. Elan put itself up for sale on Friday.
- Tweet this
- Share this
- Digg this
- Still no sign of Malaysian jet lost in 'unprecedented mystery' |
- Missing Malaysian jet may have disintegrated in mid-air - source |
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- TIMELINE-Malaysia Airlines flight to Beijing missing in Asia
- CORRECTED-UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report